The 23rd Annual Meeting of the Japan Society for Science Policy and Research Management
Date: October 13, 2008
Venue: Institute of Industrial Science, the University of Tokyo, Tokyo JAPAN |
 |
Title (2D07): Discussion on the Innovative Methodology and Practice for the New Industrial Structure Generation in Japan |
| Summary: |
The Japanese Industry has been forced to be improved by facing the recent global industrial changes, rapid development of other Asian countries in science and technology as well as the serious decrease of our population, especially the reduction of the work forces. Under these circumstances, the new concept of novel value in economy and an aggressive strategy for the differential from other countries with the strong global strategic competitiveness will be designed and implemented.
Here we propose a novel methodology with a few practices for the generation of the novel concept of the 21st century new industrial structure and new evolution of the industry. Our proposal must be based on the global sustainability with the Japanese traditional proprietary mind-set and would be the prominent model to the rest of strategic plans in economy. Especially, we, in this symposium, emphasize our Model called " Senda-Takata New Industry Generation in Japan" that constructed based on the Japanese civilization, culture, mind-set, preference, and basic knowledge for the technology and science with supporting by the crucial role of the global relationship among academia, industry and government. We, here, propose our strategic model called "Senda-Takata Model for New Industrial Structure Generation in Japan" and will have a further discussion with all participants of this symposium in this paper. |
|
The 29th Annual Meeting of the Japan Society of Clinical Pharmacology and Therapeutics
Date: December 4, 2008
Venue: Keio Plaza Hotel, Shinjuku, Tokyo JAPAN |
|
Title (S2-1): S2-1: US-Trends on the Business and the Technology Development based on the Genetic Information for Personalized Medicine |
| Summary: |
Although the practical results from the research to clarify the correlation between diseases and genes and/or genes and drugs (pharmacogenomics and pharmacogenetics) have not been recognized many so far, the development of the diagnostic instrumentation and business based on the genetetic information has been in progress urgently. In the US market, Genetic Analysis Services business, such as congenital hereditary disease, SNPs (single nucleotide polymorphism) & genotype analyses for the reactiveness to a specific drug, identification of cancer type, prognosis of the recurrence of the breast cancer, prognosis of the acute rejection of heart transplantation (multi-gene expression profiling) has emerged currently. On the other hand, whole genome read-through technologies also have come on the market.
The development of diagnostic instrumentation is required as quick, easy, precise, inexpensive, and small, at such as 'point-of-care' and 'lab-on-chip' which includes nanotechnology, microfluidics and biochip on the market.
In this paper, this kind of novel emerging technologies and new business in the US trends will be summarized and discussed. |
|
|
